VERDICT
Depends
Should I use Waystar?
Cloud-based healthcare revenue cycle management: claims, payments, prior authorization, AI - waystar.com
· 12 hours ago
Buy if you run a hospital, health system, or high-volume billing operation that needs enterprise-grade claims and payment automation. Skip it if you are a small practice wanting simple, transparent billing — it is heavy and quote-priced.
Medium. Based on 30+ public sources; many snippets truncated, so several claims rest on review aggregators and company case studies.
Not published — quote-based
Enterprise
medium
No published pricing; costs likely tied to claim volume — budgeting requires a sales quote.
medium
Enterprise implementation: expect onboarding time before full claims throughput.
medium
Handles payment and patient data; verify BAA and security terms during contracting.
medium
Ongoing sale/ownership exploration could affect roadmap and support continuity.
Value for money: 2/5
Rating
Not published — quote-based
Starting price
10
Sources
Analyzed
Not published — quote-based
No known vulnerabilities found in the sources reviewed.
Billing professionals on forums are highly positive and review sites rate it near the top of its category.
“I love waystar.”
Compare Waystar with each alternative.
EHR with built-in RCM for practices
EHR with integrated clearinghouse for smaller practices
Enterprise clearinghouse competitor at similar scale
All-in-one EHR and billing for small practices
Based on 30+ public sources; many snippets truncated, so several claims rest on review aggregators and company case studies.
Enterprise healthcare RCM trusted by big health systems. Quote-priced and overkill for small practices and non-healthcare teams.
Based on 30+ public sources; many snippets truncated, so several claims rest on review aggregators and company case studies.
Anonymous. You can change your vote.
Loading votes…
Comments
One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.
No comments yet.